Cargando…
Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
Chirality is a major theme in the design, discovery, and development of new drugs. Historically, pharmaceuticals have been synthesized as racemic mixtures. However, the enantiomeric forms of drug molecules have distinct biological properties. One enantiomer may be responsible for the desired therape...
Autores principales: | Tamatam, Rekha, Shin, Dongyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052577/ https://www.ncbi.nlm.nih.gov/pubmed/36986439 http://dx.doi.org/10.3390/ph16030339 |
Ejemplares similares
-
Recent Advances in the Transition-Metal-Free Synthesis of Quinazolines
por: Tamatam, Rekha, et al.
Publicado: (2023) -
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021) -
Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023) -
Transition-metal-catalyzed synthesis of quinazolines: A review
por: Tamatam, Rekha, et al.
Publicado: (2023) -
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)